AstraZeneca PLC
AZNNYSEHealthcare● Active
$183.75
$-2.20(-1.18%)
Market Cap$285.0B
P/E Ratio—
52W High$212.71
52W Low$137.22
外国私人发行人 · 提交 20-F / 6-K
AstraZeneca PLC（AZN）SEC 证券文件与年度报告
基于 SEC EDGAR 的监管申报（10-K、10-Q、8-K）、最新类型与完整申报历史；下方可跳转财务报表与盈利数据。
SEC EDGAR · data.sec.gov · CIK 0000901832 · AZN · NYSE · 截至 2026年6月8日
数据来源：SEC EDGAR (data.sec.gov) · CIK 0000901832 · 每小时更新 · 非投资建议
最新年度报告
20-F · 年度报告（外国发行人）财年
提交日期
2026-02-24
财年末
Feb 24, 2026
受理编号
0001104659-26-019130
主要文件
azn-20251231x20f.htm
数据来源：data.sec.gov · CIK 0000901832 · 受理号 0001104659-26-019130
最新关键披露
6-K季度报告
8-K即时报告
暂无最新申报
Form 4内幕交易
SEC 申报历史
隐藏 Form 4 / 144
提交日期
文件类型
说明
查看
2026-06-01
6-K
Current Report (Foreign Issuer)
ADMISSION OF FURTHER SECURITIES TO TRADING
0001654954-26-005587
6-KCurrent Report (Foreign Issuer)
ADMISSION OF FURTHER SECURITIES TO TRADING
2026-06-01
6-KCurrent Report (Foreign Issuer)
TOTAL VOTING RIGHTS
2026-06-01
2026-05-29
6-K
Current Report (Foreign Issuer)
IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER
0001654954-26-005498
6-KCurrent Report (Foreign Issuer)
IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER
2026-05-29
2026-05-27
6-K
Current Report (Foreign Issuer)
US FDA DECISION DATE ON CAMIZESTRANT EXTENDED
0001654954-26-005381
6-KCurrent Report (Foreign Issuer)
US FDA DECISION DATE ON CAMIZESTRANT EXTENDED
2026-05-27
2026-05-26
6-K
Current Report (Foreign Issuer)
DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC
0001654954-26-005309
6-KCurrent Report (Foreign Issuer)
DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC
2026-05-26
2026-05-26
6-K
Current Report (Foreign Issuer)
ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS
0001654954-26-005306
6-KCurrent Report (Foreign Issuer)
ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS
2026-05-26
2026-05-26
6-K
Current Report (Foreign Issuer)
CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU
0001654954-26-005303
6-KCurrent Report (Foreign Issuer)
CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU
2026-05-26
6-KCurrent Report (Foreign Issuer)
DIRECTOR/PDMR SHAREHOLDING
2026-05-18
2026-05-18
6-K
Current Report (Foreign Issuer)
BAXFENDY APPROVED IN THE US FOR HYPERTENSION
0001654954-26-005044
6-KCurrent Report (Foreign Issuer)
BAXFENDY APPROVED IN THE US FOR HYPERTENSION
2026-05-18
2026-05-18
6-K
Current Report (Foreign Issuer)
ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS
0001654954-26-005038
6-KCurrent Report (Foreign Issuer)
ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS
2026-05-18
2026-05-14
6-K
Current Report (Foreign Issuer)
IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER
0001654954-26-004836
6-KCurrent Report (Foreign Issuer)
IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER
2026-05-14
2026-05-01
6-K
Current Report (Foreign Issuer)
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES
0001654954-26-004247
6-KCurrent Report (Foreign Issuer)
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES
2026-05-01
2026-05-01
6-K
Current Report (Foreign Issuer)
FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER
0001654954-26-004229
6-KCurrent Report (Foreign Issuer)
FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER
2026-05-01
显示 1–15，共 993 条Form 4 / 144 已隐藏· EDGAR 共 1000 条
关于 SEC 申报文件与 10-K 年报
数据来源： SEC EDGAR (data.sec.gov) | 更新时间： Hourly | CIK： 0000901832 | 交易所： NYSE · Healthcare
AstraZeneca PLC（NYSE：AZN）自 1993 年 IPO 以来已向美国证券交易委员会（SEC）提交 1,000+ 份文件。CIK 为 0000901832，所有申报文件均可通过 SEC EDGAR 数据库免费查阅。
10-K 年度报告是 AstraZeneca PLC 最全面的监管披露文件。最新 AZN 10-K 于 2026-02-24 提交，财年截至 2026。历史年报可查阅 2019 至 2026 年度。
投资者可通过上方链接直接访问 AstraZeneca PLC SEC 申报文件，包括 10-K 年报、10-Q 季报、8-K 即时披露及代理声明（DEF 14A）。
数据来源：SEC EDGAR · data.sec.gov · Form 10-K · 10-Q · 8-K2026-06-08
相关公司 SEC 申报 — Healthcare
常见问题
AZN SEC 申报 · 8 个问题AstraZeneca PLC（AZN）的 SEC 申报文件可在本页及 SEC EDGAR（sec.gov）免费查阅。CIK 为 0000901832。
AZN SEC 申报AstraZeneca PLC SEC 文件AZN 10-K 查找